http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CH-532008-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c902faf6ae746c51fc8010672fc22894 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C405-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P31-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C405-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P31-00 |
| filingDate | 1969-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4233ed7a09bc5af27ac74288bf8c959a |
| publicationDate | 1972-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CH-532008-A |
| titleOfInvention | Process for the production of prostaglandin derivatives |
| abstract | Prostaglandin analogues (II) are new compds. prepared by reacting water at 0-60 C with disulphenic esters of formula I, which may have the exo- or endv configuration. (which n is 1-8; a is 0-4; R15 is C1-4 alkyl or -CH2CCl3: Y = i-butyl, t-butyl, 3,3- difluorobutyl, 4,4-difluorobutyl, or 4,4,4-triflurorbutyl; is approx. indicates that the -(CH2)n-COOR15 group is in alpha- or beta-configuration relative to the ring; R6 is C1-5 alkyl) - Advantages/uses:- the cpds. II and III and their derivatives are analogous to prostaglandin E, prostaglandin F and prostaglandin A in their bilogical activity, but are much more specific in action. As the present compounds have a narrower biological spectrum, their use is generally attended by a lesser degree of undesired side actions than for the natural prostaglandins. In addition, some of the synthetic compounds show a higher biological response than the natural prostaglandins in a specific area. |
| priorityDate | 1968-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 285.